Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2014-08-14 Interim / Quarterly Rep…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 30 June 2014 2 pages 295.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Preliminary Final Report 30 June 2014' and is an ASX announcement by Living Cell Technologies Limited. It references the Appendix 4E report for the year ended 30 June 2014, which is a regulatory requirement for preliminary final reports in Australia. The text includes financial results for the full fiscal year, such as net loss and cash balance, and discusses business progress and clinical trials. The document is about the full-year financial results and operational highlights, consistent with an annual report or preliminary final report. The document length is 5605 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement of a report. Therefore, this document is best classified as an Interim / Quarterly Report (IR) because the Appendix 4E is typically a preliminary final report, which is a comprehensive financial report for the fiscal year but not the full annual report (10-K). However, since it is a preliminary final report (Appendix 4E) and not the full annual report, the closest fitting category is Interim / Quarterly Report (IR). FY 2014
2014-08-14 English
Change of Director's Interest Notice 3 pages 37.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of securities held before and after the change, the nature of the transaction (on-market trade), and other related information. This is a clear report of a personal share transaction by a company director. The document length is 3916 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is a general regulatory filing or an announcement of a report. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2014-07-31 English
Appendix 4C - quarterly 5 pages 53.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated cash flow statements for the quarter ended 30 June 2014. It includes operating, investing, and financing cash flows, payments to directors, reconciliation of cash, and compliance statements. The document is a quarterly financial report with substantive financial data and analysis, not merely an announcement or certification. The length is over 6,800 characters, indicating it is a full report rather than a brief notice. The content aligns with the definition of an Interim / Quarterly Report (IR), which covers comprehensive financial data for a period shorter than a full fiscal year. Q4 2014
2014-07-29 English
Appendix 4C Announcement 2 pages 50.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 June 2014' and is an ASX announcement. It provides a summary of the company's quarterly cash flow, including cash balances, net operating cash flow, receipts from customers, and operating payments for the quarter ended 30 June 2014. The document contains actual financial data for a quarter, which is a period shorter than a full fiscal year. It is not merely an announcement of a report being published or attached, but includes substantive financial information. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2014
2014-07-29 English
Dr Ken Taylor appointed Chief Executive 2 pages 69.0KB
Board/Management Information Classification · 95% confidence The document is an announcement from Living Cell Technologies Limited regarding the appointment of Dr. Ken Taylor as Chief Executive. It provides background information on Dr. Taylor's career and qualifications, as well as a brief overview of the company's business and products. There are no financial statements, detailed financial performance data, or regulatory filings included. The document is a corporate announcement about a management change, specifically the appointment of a new CEO. This fits the category of Board/Management Information (MANG). The document length (6204 characters) and content confirm it is not a brief notice or a report publication announcement but a substantive announcement about management changes.
2014-07-07 English
Chief Executive's Remuneration 2 pages 50.4KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 8 July 2014. It announces the appointment of Dr Ken Taylor as Chief Executive and details his remuneration package, including salary and share options. The content focuses solely on management appointment and remuneration details, without any financial statements, earnings data, or regulatory filings. The document length is 4550 characters, which is relatively short and contains no indication of being a report or a certification. The key focus is on management information, specifically the appointment and remuneration of a senior executive. Therefore, the document fits best under the category of Board/Management Information (MANG).
2014-07-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.